This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Adjuvant Therapeutic Effects of Galantamine on Apathy in a Schizophrenia Patient

David S. Arnold, MD; Richard B. Rosse, MD; Dwight Dickinson, PhD; Rhonda Benham, RN; Stephen I. Deutsch, MD, PhD; Matthew W. Nelson, PharmD

Published: December 15, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The limitations of the current medications used to treat schizophrenia have led to a search for adjunctive treatments that may better address the negative symptoms, cognitive deficits, and behavioral problems of the disorder. A promising strategy might be adopted from the current use of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease.1 Acetylcholinesterase inhibitors (e.g., tacrine, donepezil) improve general cognitive functioning and reduce apathy, anxiety, agitation, and other psychiatric symptoms in Alzheimer’s patients. Galantamine has a dual mechanism of action that may offer particular benefits for individuals with schizophrenia.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...